Wellgistics Health, Inc.

Experienced Healthcare Information Technology Specialist Joins Leading Pharmaceutical IT Company

• Executives exercise previously issued warrants to acquire 200,000 common shares

• Shares issued in connection with exercise added to existing lock-up agreements

• Name reflects vertically-aligned healthcare ecosystem business model integrating data captured via telemedicine, online pharmacy, lab tests and wearables to perfect patients' digital health twins in the Health Lives Here app designed to influence/optimize behavior

• EinsteinRx AI^™ capabilities expanding into medical, laboratory and wearables fields

• Pharmacy and Pharmacy Services division being rebranded as Corexa Health^™

• Company positioned to empower patients to seize ownership of their health data with blockchain-enabled data management to control data and participate in its monetization

• (1) 2,647,198 common shares outstanding, with (2) 1,333,930 of those shares locked up for at least ninety (90) days from today, and (3) 919,465 common shares deposited in DTCC, leaving (4) 80,628 cash warrants with fixed $35.00 exercise price representing only other securities currently eligible for deposit into DTCC for free trading shares

• Focus is on closing DelivMeds AI transaction, driving pharmacy revenue growth and supporting PharmacyChain™, Medical Drones and Health Lives Here progress

• Recent capital raise provides capital into late 2026, including meeting criteria for DelivMeds AI transaction funding closing condition

• Recent capital raise and debt restructuring preclude the Company from issuing shares for capital raising purposes until the earlier of seven (7) months from the transaction date and thirty (30) days after effectiveness of the resale registration statement covering the underlying securities.

• Recent lock-up agreement to limit shares available for sale into the market

• Exercise of warrants embedded in recent financing would provide funding through 2029

• Holders of 1,333,930 common shares agree to minimum 90-day lock-up agreement

• New oversubscribed $21 million convertible debt instrument ("New Debt") refinances all outstanding convertible debt, provides $6.5 million in new capital for working capital and general corporate purposes does not accrue interest and converts into common shares at $6.00 per share

• Automatic Exchange provision automatically converts the New Debt into Preferred Stock upon the effectiveness of a registration statement and attainment of shareholder approval for the creation of Preferred Stock

• The class of Preferred Stock that the New Convertible Debt exchanges into (the "Funding Preferred") converts into common shares at $50.00 per share

• New funds raised satisfy capital raising closing condition from Fully Binding Term Sheet with Datavault AI, EOS Technology Holdings, Scilex Pharma and HealthBridge Advisors

• 1-for-50 reverse split of common shares outstanding now complete

• 2,513,425 common shares now outstanding

• A new CUSIP was issued in connection with reverse split

This Press Release updates the information from the previous release.

Why Vertical Integration and Blockchain Will Define the Next Era of Healthcare

Why Vertical Integration and Blockchain Will Define the Next Era of Healthcare

• Wellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026, based on preliminary unaudited results

• Q1-26 focus on optimization of Wellgistics Pharmacy revenue growth and capabilities positions Company to integrate emerging licensed PharmacyChain™ pharmacy data tokenization technology into pharmacy dispensing AI hub EinsteinRx™

• Kare Pharmtech joint venture expands the Company's telepharmacy and direct-to-patient capabilities, providing immediate access to 200,000+ patient lives

• Strategic partnership with Tollo Health provides access to proprietary pharmaceutical-adjunct medical foods & dietary supplements, telemedicine and mental health AI coaching & regimen compliance tools via "Health Lives Here" app that is targeted to launch in August 2026 following the reveal with NFL Alumni Health at 2026 NFL Draft in Pittsburgh

• The Company is in advanced discussions with Datavault AI regarding a binding term sheet to expand the scope of the PharmacyChain™ license to include Health-as-a-Service (HaaS) capabilities

• Company has terminated previously announced non-binding letters of intent with Neuritek and WellCare and does not intend to proceed with those transactions

Highlights:

• WellCare Today brings established RPM, RTM and CCM infrastructure with wearable technology integrations and connected monitoring solutions

• Combination expected to integrate Wellgistics Health recently announced MSO initiative with Kare Clinicals and its network of 6,500+ independent pharmacies

• Proposed platform designed to enhance patient engagement, medication adherence, remote monitoring and longitudinal care coordination

• Proposed transaction valued at approximately $15 million

• Strategic initiative intended to create additional clinical revenue opportunities for participating pharmacies and providers

Highlights:

• According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹

• Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructure

• Approximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providers

• Wellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiatives

• Participating pharmacists expected to gain access to new clinical service revenue opportunities

• Joint venture executed combining Wellgistics Hub and KareRx Hub technology and operations

• Integrated platform accelerates pharmaceutical access, fulfillment, and commercialization

• Combined ecosystem provides potential reach to an estimated 200,000+ patient lives across pharmaceutical and provider networks

• Medical insurance eligibility and benefits verification (EBV) is a core health technology capability necessary for PharmacyChain™ to gain market adoption

• EBV services offering enabled with preferred pricing being made immediately available to providers, partners and the Wellgistics Pharmacy Network

• EBV market expected to grow from $2.39 billion in 2025 to $3 billion in 2030 according to The Business Research Company¹

• GLP-1 agonist market expected to grow from $70B in 2025 to $201B in 2030¹

• Proprietary Forzet formulation provides pharmacists, physicians and patients with unique solution for GLP-1 drugs' primary side effect

• Forzet targeting preservation of muscle while on GLP-1 agonist therapy to facilitate continued patient adherence and muscle redevelopment following therapy discontinuation to help mitigate weight regain

   

• Hyperledger Fabric, Ethereum/Polygon, VeChain, Quorum /Besu and Corda (R3) selected as most suitable blockchain platforms to build PharmacyChain^™

• U.S. prescription drugs market project to grow from $634 billion market to $883 billion by 2030 according to Grandview Research^[1]

• Global blockchain in healthcare market is projected to grow from $11 billion in 2024 to $214 billion by 2030, according to Grandview Research^[2]

• Previously announced partnership with Tollo Health subsidiary TolloCare adding telehealth service offering to drive Wellgistics Pharmacy prescription drug dispending of GLP-1 drugs and promote patient engagement via mental health AI software solution for compliance and to promote lifestyle changes

• Tollo Health recently formed subsidiary TolloCare, LLC ('TolloCare') initially targeted to provide telehealth services for GLP-1 and Long COVID patients

• TolloCare has white-labeled telehealth capabilities via a telemedicine company with over 5,000 onboarded physicians nationwide to provide synchronous and asynchronous medical services, including prescriptions, for weight loss and separately will cultivate a Long COVD physician base

• Tollo Health has entered into agreement to expand TolloCare capabilities via a partnership with a stealth San Francisco Bay Area startup preparing to deploy a mental health AI app with unique tools to engage with patients

• Wellgistics Health to leverage EinsteinRx™ AI pharmacy hub and PharmacyChain™ smart contracts to drive healthcare optimization for former NFL players that and rural communities

• Focus areas include mental health, weight loss, sleep apnea, cardiometabolic disease, pain management and Long COVID

• NFL Alumni Health Ambassadors to help support Wellgistics' healthcare access and ease-of-use message to rural communities though Wellgistics' pharmacy and independent pharmacy network

• Wellgistics and NLF Alumni Health management attended 'Radio Row' during week of Super Bowl LX in San Francisco

• Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRx™ into pharmacy client point-of-sales systems has commenced

• EinsteinRx integration streamlining effort focuses on reducing onboarding process friction and speeding time to implementation prior to scaling pharmacy marketing effort

• Company expects to onboard up to 500 pharmacies per month into formal Wellgistics Pharmacy Network by year end 2026

• Manufacturer supplier relationship expansion effort focused on diabetes, weight loss, cardiometabolic & Long COVID patients that existing pharmacy clients already serve

• PharmacyChain™ blockchain-enabled healthcare smart contract development resource assessment ongoing

• Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash price

• Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to educate patients and providers on the advantages of Brenzavvy vs. Jardiance® and other SGLT-2 inhibitors

• Reduced out-of-pocket costs for patients, paired with a patient-education revenue opportunity for pharmacists, are designed to support broader market access to Brenzavvy and enhance the overall care experience

• Launch establishes a new model for next-generation reformulated drugs that offer patient-specific product advantages compared with entrenched market leaders

• Company plans to distribute Dream Bowl 2026 Meme Coin to shareholders as of a to-be-determined December 2025 date with distribution expected in January 2026

• Consolidates messaging around Einstein Rx AI, Wellgistics Hub (formerly DelivMeds) and HubRx AI integration with pharmacies (in-house pharmacy and 6,500+ independent pharmacy network), physicians and manufacturers

• Integration of technology and physical infrastructure positions Wellgistics with the "Pharmacy IT Railroad" to execute on PharmacyChain™ smart contracts for optimized healthcare delivery in the $634 billion United States prescription drug market

In partnership with RxERP Financial, the program offers up to $350,000 per pharmacy and $1 million per wholesaler or manufacturer through trusted third-party financing partners, strengthening cash flow and supply chain resilience.